- Home
- / ChemomAb
ChemomAb
Stock Price
$1.4
2024-10-29
Market Capitalization
$28.1 M
2024-10-29
ChemomAb Summary
Company Summary
- Overview
- ChemomAb is a clinical stage biopharmaceutical company which develops therapeutic antibodies for the treatment of autoimmune and inflammatory diseases. The Company specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Tel Aviv-Yafo, IL | view all locations
- Website
- http://chemomab.com/
- Cybersecurity rating
Table of Contents
Key People
Alan Moses, Director
Claude Nicaise, Director
Neil Cohen, Director
LocationsView all
1 location detected
Tel Aviv-Yafo, Tel Aviv District HQ
Israel
Kiryat Atidim
ChemomAb Financials
Summary Financials
- Net income (Q1, 2026)
- ($1.8M)
- Cash (Q1, 2026)
- $5.9M
- EBIT (Q1, 2026)
- ($1.9M)